Nanordica Medical is happy to announce that we started one of the world’s most ambitious clinical trials in wound care on the most challenging wounds: diabetic foot ulcers (DFU). The trial, involving 5 clinical centers and 170 patients, is coordinated by the leading international DFU expert, Prof. Dr. José Luis Lázaro-Martínez.

In this trial, the safety and performance after treatment with Nanordica Medical wound dressing is compared to those of one of the leading wound dressings. The primary endpoint of the study is a complete wound closure at 12 weeks, together with several secondary endpoints. Our ambition is to advance evidence-based wound care and contribute to the best practices in treating diabetic foot ulcers and beyond.

Nanordica advanced antibacterial wound dressing is made of natural silk nanofibers containing Premotiv nanotechnology. This design represents a novel concept in wound care aiming to PREvent infection and proMOTe wound closure simultaneously, leading to faster wound healing.

The study is expected to finish in March 2026 and is co-financed by the EIC Accelerator project (European Innovation Council and SMEs Executive Agency (EISMEA). More information is in comments. If you wish collaborate within the study, please get in touch with our Chief Clinical Officer Dr. Grigory Vasiliev.

In the picture is the Principal Investigator of the clinical study Prof. Dr. José Luis Lázaro-Martínez (Complutense University of Madrid, Spain) and Nanordica Medical’s Chief Clinical Officer Dr. Grigory Vasiliev responsible for the study design.

Read more about the trial on clinicaltrials.gov.